Featured Story

Studying Tumor Fusion Burden with Bioinformatics

 Dna helix connected by nodes and connections colored.

Prostate cancer is the second leading cause of cancer-associated death in men. Work recently published by Genentech along with their partners at Fios Genomics demonstrated gene expression patterns from a clinical collection of 192 prostate tissue samples to determine changes in molecular and immune expression. It was determined that tumor fusion burden (TFB) is a pathophysiological hallmark of immune infiltration in prostate cancer.

Read the Case Study